Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hyperosmolarity enhances the lung capillary barrier
Zeenat Safdar, … , Sadiqa Quadri, Jahar Bhattacharya
Zeenat Safdar, … , Sadiqa Quadri, Jahar Bhattacharya
Published November 15, 2003
Citation Information: J Clin Invest. 2003;112(10):1541-1549. https://doi.org/10.1172/JCI18370.
View: Text | PDF
Article Cell biology

Hyperosmolarity enhances the lung capillary barrier

  • Text
  • PDF
Abstract

Although capillary barrier deterioration underlies major inflammatory lung pathology, barrier-enhancing strategies are not available. To consider hyperosmolar therapy as a possible strategy, we gave 15-minute infusions of hyperosmolar sucrose in lung venular capillaries imaged in real time. Surprisingly, this treatment enhanced the capillary barrier, as indicated by quantification of the capillary hydraulic conductivity. The barrier enhancement was sufficient to block the injurious effects of thrombin, TNF-α, and H2O2 in single capillaries, and of intratracheal acid instillation in the whole lung. Capillary immunofluorescence indicated that the hyperosmolar infusion markedly augmented actin filament formation and E-cadherin expression at the endothelial cell periphery. The actin-depolymerizing agent latrunculin B abrogated the hyperosmolar barrier enhancement as well as the actin filament formation, suggesting a role for actin in the barrier response. Furthermore, hyperosmolar infusion blocked TNF-α–induced P-selectin expression in an actin-dependent manner. Our results provide the first evidence to our knowledge that in lung capillaries, hyperosmolarity remodels the endothelial barrier and the actin cytoskeleton to enhance barrier properties and block proinflammatory secretory processes. Hyperosmolar therapy may be beneficial in lung inflammatory disease.

Authors

Zeenat Safdar, Ping Wang, Hideo Ichimura, Andrew C. Issekutz, Sadiqa Quadri, Jahar Bhattacharya

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Confocal microscopy of actin fluorescence in lung capillaries. (a and b)...
Confocal microscopy of actin fluorescence in lung capillaries. (a and b) Images show single capillaries that received 15-minute infusions as indicated. Camera gain was set as shown. Red pseudocolor reflects fluorescence of rhodamine-phalloidin. Replicated four times. (c) Bars represent responses to infusions of isosmolar buffer and hyperosmolar sucrose given alone, hyperosmolar sucrose given with genistein (gen; 50 μM) or latrunculin B (lat; 100 nM), and genistein, latrunculin B, or jasplakinolide (jsp; 100 nM) given alone. Mean ± SD; n, number of experiments. *P < 0.05 compared with isosmolar infusion; **P < 0.05 compared with hyperosmolar infusion. iso, isosmolar Ringer’s buffer (300 mosm); hyp, hyperosmolar sucrose (350 mosm).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts